HPA Axis Dysfunction, Hypocortisolism & Adrenal Dynamics in ME/CFS & Long COVID: The Yale Nature Biomarker Findings & Diurnal Salivary Profiling

1. The Yale Nature Biomarker Discovery: Objective Hypocortisolism in Post-Viral Syndromes

For decades, patient reports of extreme morning exhaustion, inability to tolerate physiological stress, orthostatic intolerance, and salt cravings were dismissed by clinicians relying solely on standard random morning serum cortisol blood draws. Because serum cortisol reflects total hormone (over 90% of which is biologically inactive, bound to Corticosteroid-Binding Globulin [CBG] and albumin), subtle free cortisol deficits were systematically missed.

In September 2023, a seminal study led by Prof. Akiko Iwasaki, David Putrino, and Jon Klein at Yale University School of Medicine and the Icahn School of Medicine at Mount Sinai fundamentally transformed the field PMID: 37748514. In a comprehensive multi-omic investigation of 273 individuals (comprising post-COVID ME/CFS cohorts, convalescent controls, and healthy controls), machine learning models identified circulating cortisol as the single most powerful biological discriminator differentiating patients from healthy individuals.

Mean morning cortisol concentrations in the patient cohort were approximately half those of healthy matched controls. Remarkably, this marked reduction in cortisol was accompanied by normal or subnormally low levels of Adrenocorticotropic Hormone (ACTH). In primary adrenal failure, the pituitary responds to low cortisol by pumping out massive surges of ACTH. The complete absence of compensatory ACTH hypersecretion in ME/CFS and Long COVID pinpointed the primary lesion: a failure of central hypothalamic corticotropin-releasing hormone (CRH) and pituitary signaling PMID: 37748514.

2. Neuro-Endocrine Pathophysiology: Hypothalamic Blunting & Glucocorticoid Receptor Hypersensitivity

Why does the central nervous system down-regulate the adrenal response in ME/CFS? Evidence indicates that central HPA axis suppression is an adaptive, protective "energy conservation" mechanism that becomes pathologically locked in place:

• Microglial Priming in the Hypothalamus: Persistent neuroinflammation, viral antigens (EBV, HHV-6, SARS-CoV-2 spike protein), or circulating cytokines (IL-1β, TNF-α, IL-6) activate microglia surrounding the paraventricular nucleus (PVN) of the hypothalamus. Chronic cytokine exposure disrupts normal pulsatile CRH synthesis, suppressing downstream pituitary-adrenal activation PMID: 21855298.
• Hypersensitivity of Glucocorticoid Receptor Negative Feedback: Very-low-dose Dexamethasone Suppression Testing (0.5 mg) reveals that ME/CFS patients exhibit heightened feedback inhibition. Even minimal circulating cortisol concentrations trigger exaggerated shutdown of CRH and ACTH release at the level of the hippocampus and pituitary gland.
• Blunted Cortisol Awakening Response (CAR): Upon awakening, the transition from darkness to light and the conscious anticipation of the day triggers the suprachiasmatic nucleus (SCN) to stimulate a rapid 50–75% surge in free cortisol within 30 to 45 minutes. This CAR surge performs critical homeostatic duties: raising blood pressure, elevating blood glucose, and suppressing nocturnal inflammatory cytokines. In ME/CFS, the blunted CAR leaves patients with severe morning sleep inertia, hypotension, orthostatic intolerance, and profound brain fog that takes hours to overcome PMID: 17920194.
• The "Tired but Wired" Inverted Curve: As diurnal cortisol flatlines during the daylight hours, the circadian rhythm of melatonin and evening cortisol becomes desynchronized. Many patients exhibit a paradoxical late-night spike in cortisol, leading to bedtime agitation, racing thoughts, and sleep onset insomnia.

3. The Dangers of High-Dose Hydrocortisone: Why Replacement Fails

Given the clear evidence of hypocortisolism in ME/CFS and Long COVID, many practitioners are tempted to prescribe standard pharmacological replacement doses of hydrocortisone (20 to 30 mg daily). However, landmark randomized controlled trials have demonstrated that this approach carries significant clinical risks PMID: 11268333.

In a classic trial by McKenzie, Straus et al. published in JAMA, ME/CFS patients treated with 25–30 mg of hydrocortisone experienced significant short-term improvements in fatigue scores. However, over 25% of treated patients developed objective laboratory evidence of endogenous adrenal gland atrophy (suppressed morning corticotropin-stimulated cortisol production). Furthermore, discontinuation led to severe post-treatment rebound crashes and adrenal crisis risks.

Because the adrenal cortex itself is healthy and responsive, floods of exogenous hydrocortisone trigger negative feedback loops, shutting down the remaining endogenous hypothalamic CRH output. Modern clinical protocols therefore restrict steroid usage to micro-physiological support or focus on non-suppressive neuro-endocrine restorative strategies:

The DHEA-S to Cortisol Ratio & Neurosteroid Depletion

Beyond free cortisol, evaluating dehydroepiandrosterone sulfate (DHEA-S) is critical for assessing the anabolic-to-catabolic balance in ME/CFS. DHEA-S is an adrenal neurosteroid that functions as an endogenous antagonist to cortisol's catabolic effects in neural tissue, supporting neurogenesis, synaptic plasticity, and immune cell proliferation. In healthy physiology, the adrenal glands produce DHEA-S and cortisol in a regulated ratio.

In prolonged ME/CFS, chronic central HPA axis blunting often leads to severe DHEA-S exhaustion. A depressed DHEA-S to cortisol ratio indicates an environment of unchecked catabolic breakdown, cellular senescence, and impaired microglial recovery. Clinical protocols often consider physiological DHEA supplementation (5–15 mg in women, 15–25 mg in men, dosed in the morning) with regular monitoring of serum DHEA-S and downstream sex steroid metabolites (estradiol and testosterone) to restore neurosteroid equilibrium.